A p-value of 0.09 is not a typo, and the fact that it appears in a Lancet publication of Capricor’s HOPE-3 Phase 3 results tells you something important about the moment deramiocel is in. Capricor disclosed on July 29, 2026, via an SEC Form 8-K, that the updated statistical model for left ventricular ejection fraction produced that p-value alongside a 1.8 percentage point treatment difference in the overall study population. The prior model had yielded a different result. That methodological revision, developed through ongoing FDA dialogue and in response to peer review requirements from The Lancet itself, is the defining tension in this dataset.
Deramiocel is an allogeneic cardiosphere-derived cell therapy targeting the cardiac complications of Duchenne muscular dystrophyDuchenne muscular dystrophy. DMD cardiomyopathy is progressive and eventually fatal, managed with off-label regimens adapted from broader heart failure evidence. The HOPE-3 trial was designed to show that deramiocel could protect or improve cardiac function over one year. A 1.8 percentage point LVEF difference is not trivial in a disease where the myocardium deteriorates steadily and options are limited, but reaching statistical significance at the conventional 0.05 threshold is a different matter than p equals 0.09. Regulatory reviewers do not grade on a curve simply because the biology is compelling.
The model change itself demands scrutiny. Revisions to a primary endpoint analysis model, even when conducted transparently through FDA engagement, create a legitimate question about what the pre-specified plan showed versus what the revised plan showed. The Lancet’s peer review process presumably interrogated that distinction, and publication implies the journal found the methodology defensible. Still, the FDA’s own bioresearch monitoring inspection, flagged in the same disclosure, adds a layer of procedural complexity that Capricor will need to address cleanly before any BLA conversation becomes straightforward.
The single number to watch from here is not the p-value itself but the FDA’s written response to the LVEF model change and its consistency with whatever statistical analysis plan was originally filed. That response, whenever it surfaces in a subsequent public disclosure, will define whether HOPE-3 supports a regulatory filing or requires additional data to bridge the gap between a promising treatment difference and the evidentiary standard an approval demands.
Source link: https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
